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Introduction
Fibrosis is a hallmark pathological feature of end-stage organ damage. 1 Persistent pathological stimulation promotes a plethora of responses including inflammatory cell infiltration, destruction of parenchymal cell structure, excess extracellular matrix (ECM) deposition by myofibroblasts, and lack of tissue reconstruction. These responses, in turn, provide for a vicious cycle which subsequently leads to fibrosis and organ failure. 2 Cardiac fibrosis is initiated by direct injury (e.g. ischemia, viral infection), hemodynamic insult (e.g. hypertension, pressure overload) in addition to neurohormonal stimulation (e.g.
angiotensin II). 3 A milieu of cells such as cardiomyocytes, cardiac fibroblasts, inflammatory cells and endothelial cells, in addition to bioactive molecules such as chemokines/cytokines and extra-cellular matrix factors are involved in this response. 4 Deciphering the underlying mechanisms of this process have proven difficult in part due to the complicated cell to cell hierarchy and interactions that are involved. 5 Recent progress has been made to understand the origin of myofibroblasts by fate mapping; however, mechanisms and regulation of cell to cell interaction and communication within the heart and its constituent cells in cardiac fibrosis remain unclear. 6, 7 Better understanding of regulatory and mechanistic processes are important as they would provide direct therapeutic targets for modulation by drugs and/or antibody therapy in the prevention and treatment of end-organ damage.
KLFs are transcription factors which play diverse roles in tissue remodeling in response to pathological stimuli such as pressure overload and neurohormonal factors (e.g. angiotensin II). [8] [9] [10] [11] has been reported to regulate the hepatic stellate cell which plays a central role in liver fibrosis, 12 and hepatic cell-specific deletion of this factor has been reported to show reduced severity of liver lipo-fibrosis. 13 In the cardiovasculature, homozygous mutation of Klf6 results in embryonic lethality with diminished yolk sac vasculature suggesting involvement in cardiovascular development. 14 We therefore hypothesized that KLF6 might regulate fibrosis of the heart and investigated roles of KLF6 in regulating pathological cardiac fibrosis in the present study, and find that KLF6 in cardiomyocytes regulates cardiac fibrosis through transcriptional control of the extra-cellular matrix (ECM) factor, thrombospondin 4 (TSP4), in response to angiotensin II stimulation. Through our studies, we identify a new intercellular regulatory mechanism whereby cardiomyocytes modulate cardiac fibroblast functions and the fibrotic/remodeling response. and subjected to prior approval by the local animal protection authority in the University of Tokyo Ethics
Committee for Animal Experiments (Reference Number: P10-040).
Heterozygous deletion of KLF6 (Klf6
) in C57BL/6J mice were generated as previously described. 15 To generate cardiomyocyte-and cardiac fibroblast-specific Klf6-knockout mice, Klf6 flox/-and Klf6 flox/flox mice were respectively cross-bred with αMHC-Cre and POSTN-Cre mice. TSP4 knockout mice were obtained from The Jackson Laboratory and further back-crossed with C57BL/6J mice.
Angiotensin II induced cardiac fibrosis
To induce cardiac fibrosis, we subjected mice to continuous angiotensin II infusion as described previously. 9 Briefly, mice (8-10 week old males) were anesthetized with intra-peritoneal administration of xylazine (5 mg/kg) and ketamine (100 mg/kg). Angiotensin II (Wako, Osaka, Japan) dissolved in 0.15 mo/L NaCl and 1 mmol/L acetic acid solution was subcutaneously administered by osmotic pump (Alzet model 2002, Alza Corp, Mountain View, California) at the rate of 3.2 mg/kg/day for 3 days to 14 days to 8-to 10-week old mice. After 14 days angiotensin II treatment, mice were sacrificed via cervical dislocation under isofluorane (Baxter, Deerfield, IL) anesthesia (1.5%), and hearts were immediately harvested for further experiments.
Pressure overload induced by Transverse Aortic Constriction (TAC) model
TAC was performed as described previously. 10 Briefly, mice (8-10 week old males) were anesthetized with intra-peritoneal administration of xylazine (5 mg/kg) and ketamine (100 mg/kg). The mice were then intubated and ventilated with a tidal volume of 0.4 ml room air at 100 breaths/minute. After mid-sternal thoracotomy, the transverse portion of the aortic arch (between the innominate and left common carotid artery) was ligated by 10.0 silk suture tied firmly 3 times against a 26-gauge blunted needle. The thoracic cavity was closed by sternum and skin sutures. After 14 days TAC treatment, mice were sacrificed via cervical dislocation under isoflurane anesthesia (1.5%), and hearts were immediately harvested for further experiments.
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Echocardiographic analysis
Mice were lightly anesthetized with 3% inhaled isoflurane and set in a supine position. Two dimensional (2D) M-mode and Doppler echocardiography was performed using a Vevo2100 Imaging System (Visual Sonics Inc., Toronto, Canada) equipped with 18 to 38 MHz MicroScan™ transducer. The left ventricle (LV) at the papillary muscle level was imaged in 2D mode in the parasternal short-axis view.
LV diastolic posterior wall thickness (PWd), Interventricular septal thickness at end-diastole (IVSd), LV diastolic dimension (LVDd), and LV end-systolic dimension (LVDs) were measured. LV fractional shortening (FS) and ejection fraction (EF) were calculated with equipped software.
Histological analysis and immunohistochemistry
Hearts from mice were embedded in paraffin, and 5-μm-thick sections were prepared for
Masson-trichrome (MA) staining and immunostaining. Digital images of MA-stained heart were used for measurement of fibrotic area with Photoshop software (7.0, Adobe, Mountain View, California) and Image J software (NIH, http://rsbweb.nih.gov/ij/). For immunohistochemistry, after deparaffinization and blocking, mouse heart sections were incubated with the following antibodies; KLF6 (Santa Cruz Biotechnology or Biolegend). Secondary antibodies conjugated with horseradish peroxidase (Dako) and 3,3'-diamiobenzidine (DAB) (Dako) were used to confirm labeling and counter-stained with hematoxylin.
Immunofluorescent staining
For visualizing KLF6 localization in primary cultured rat neonatal cardiomyocytes and cardiac fibroblasts, anti-rabbit KLF6 antibody (Biolegend) and anti-mouse Troponin T antibody (Thermo Fischer) were used as primary antibodies, and then followed by corresponding secondary antibodies; Alex Fluor 488 or 635 (Life technologies) were used for fluorescent labelling. Nuclear staining was performed with
Hoechst33258 after the final series of washes. Finally, the specimen was mounted with Fluorescent
Mounting Medium (Dako) and then visualized with a laser confocal microscope (LSM 510, Zeiss).
Microarray analysis
Mouse genome-wide gene expression analysis was performed by using the Affymetrix Mouse Gene Fig. 6A, B) .
RNA extraction and real-time PCR
For RNA extraction and purification, we used the RNeasy mini Kit for primary cultured cells, 
Western blot analysis
Mouse heart specimens were homogenized with T-PER protein extraction buffer (Thermo scientific)
containing protease inhibitors complex (Roche) and phosphatase inhibitors (Roche). Cultured cells were homogenized with M-PER protein extraction buffer (Thermo scientific) containing protease inhibitors complex (Roche) and phosphatase inhibitors (Roche). Protein concentration was assayed using BCA protein assay kit (Pierce), and five or ten micrograms of the protein were resolved by 10% or 12% NuPAGE gels (Invitrogen) then transferred to polyvinylidene difluoride membrane (Invitrogen). The blot was probed with the following primary antibodies; KLF6 (Santa Cruz Biotechnology or Biolegend) and TSP4 (R&D). Membranes were washed and incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology). Blot for GAPDH was served as an internal control for protein loading. Labelling bands were detected by ECLplus (Thermo scientific).
Preparation of plasmid constructs and recombinant adenoviruses
The KLF6 expression vector pCAG-KLF6 was obtained by inserting the KLF6 coding cDNA into pCAGMS vector. 9 Adenoviral KLF6 construct was constructed as previously described. 17 Rat primary cultured neonatal cardiomyocytes were infected with adenoviral KLF6 or backbone adenovirus at 100 moi for 12 hour with serum free Medium 199. Then the cells were then stimulated with angiotensin II (10 μM) in fresh medium for 12 hour, and the cells were subjected to western blot.
Co-transfection reporter assay
Co-transfection reporter assay was performed as previously described using primary cultured rat neonatal cardiomyocytes (1.25 x10 5 cells/well in 24 well-plate) transfected with 200 ng of pGL3-luciferase reporter vector containing TSP4 promoter region construct and 200 ng of pCAG-KLF6 using Lipofectamine 2000 (Invitrogen). 10 Luciferase activity was measured using a luciferase assay system (Promega) and then normalized to the protein concentration in each cell lysate. Assays were done in duplicate, and expression levels of KLF6 were confirmed by immunoblotting with anti-KLF6 antibody (Santa Cruz Biotechnology).
Chromatin-immunoprecipitation (ChIP) assays
ChIP assays were performed as previously described with rat neonatal cardiomyocytes stimulated with angiotensin II (10 μM) for 24 hours prior to crosslinking for 10 minutes with 1% formaldehyde. 
Cardiac fibroblast modulation by thrombospondin 4
Modulation of cardiac fibroblast activity by matricellular TSP4 protein was evaluated as previously described with minor modification. 18 Briefly, 6-well culture plates were coated with 0.1% gelatin (Wako)
or 50 g/ml mouse recombinant TSP4 (R&D systems) for 20 hours at 4°C and then blocked with 0.5% polyvinylpyrrolidone (Sigma) for 1 hour at room temperature. 1.5 x 10 5 /well of primary cultured rat neonatal fibroblast was seeded with serum free Medium 199 (Gibco). Twelve hours after passage, the cells were stimulated with angiotensin II (10 μM) for 24 hours, and were harvested for detection of messenger RNA expression levels.
Integrin inhibition assay
Integrin blocking effect was assayed according to a previously described method. 18 Cardiac fibroblasts from wild-type mice was pre-treated for 20 minutes at 37°C with blocking antibodies to integrins and plated on recombinant TSP-4 -coated plates and stimulated with angiotensin II (10 μM) for 24 hours.
Integrin blocking antibodies; rabbit anti-integrin 3 (Biolegend), rat anti-51, anti-4 (Chemicon), and anti-M (clone M1/70, Biolegend).
Statistics
All data are presented as mean ± SD. Difference between two groups was analyzed by the Welch's t test. Comparisons between multiple groups were done using one-way or two-way ANOVA followed by a post-hoc Bonferroni test. A p value of less than 0.05 was considered significant.
Results
Klf6 haploinsufficiency results in reduced cardiac fibrosis and preserved cardiac function
) showed, in the heart, markedly decreased fibrotic deposition in response to angiotensin II overload (Fig. 1A , left panels), and decreased interstitial fibrosis compared to that of wild-type mice (quantitative analysis, Fig. 1B ), while perivascular fibrosis showed no apparent difference (Fig.1A , right panels). These results were also confirmed by biochemical analysis (Supplemental Fig.6D ). Further hemodynamic analysis showed blood-pressure independent fibrotic effects by angiotensin II stimulation (Supplemental Fig.1A-C) . Additionally, heart weight after angiotensin II by guest on Downloaded from Accepted Manuscript 9 stimulation was increased in the wild-type group compared to that of Klf6 +/-mice (Fig. 1C) . Functionally, the heart of Klf6 +/-mice exhibited lower end-diastolic pressure (Supplemental Fig. 1D , E and Supplemental table1), preserved left ventricular geometries, and systolic and diastolic function by echocardiographic examination after angiotensin II treatment (Fig.1D , E and Supplemental Fig. 2A, E) . Reduced cardiac fibrosis of Klf6 knockout mice was accompanied by decreased expression levels of fibrotic regulatory genes such as Tgfb1, Ctgf and Col1a ( Fig. 1F and Supplemental Fig. 6C ). Further, pressure overload by transverse aortic banding (TAC) to wild-type and Klf6 +/-mice did not show difference in cardiac fibrosis ( Fig. 1G and H) , relative heart weight ( Fig. 1I) , hemodynamic analysis (Supplemental Fig. 1F -H and Supplemental table1) or echocardiographic function (Supplemental Fig.2D ). To note, both angiotensin II and TAC treatment were performed for 14 days and induced significant cardiac fibrosis in wild-type mice.
However, attenuated cardiac fibrosis was detected only in angiotensin II-treated but not in TAC-treated
At the cellular level, immunohistochemical studies showed that KLF6 was specifically up-regulated in the nucleus of cardiomyocytes and not in cardiac fibroblasts under conditions of cardiac fibrosis ( Fig.   2A and B) . KLF6 was markedly induced in cardiomyocytes but not in cardiac fibroblasts as early as one day after angiotensin II stimulation, and this induction continued during stimulation thus suggesting that KLF6 may regulate the cardiac fibrotic process not through the cardiac fibroblast but by modulation of cardiomyocytes. Specific expression of KLF6 was further confirmed using cultured cardiomyocytes and fibroblasts in which KLF6 induction was seen after treatment with angiotensin II in cardiomyocytes but not in fibroblasts ( Fig. 2C and D) . Collectively, these results show that cardiomyocyte KLF6 participates in angiotensin II but not TAC-induced cardiac fibrosis.
Cardiomyocyte KLF6 expression is essential for cardiac fibrosis
To further clarify the role and importance of cardiomyocyte-specific expression of KLF6, cell type-specific KLF6-deleted mice were generated including cardiomyocyte-specific (Klf6 Fig.2B, C) . Only cardiomyocyte-specific and not the fibroblast-specific KLF6-deleted mice showed decreased cardiac fibrotic deposition in response to angiotensin II stimulation (Fig. 3A-D ;αMHC-Cre mice hearts (Supplemental Fig.6D ).
Expression levels of fibrotic marker genes (Tgfb1, Ctgf and Col1a) were also decreased in the heart of by guest on May 22, 2015
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Functional analysis by echocardiography further confirmed that Klf6 flox/-
;αMHC-Cre mice showed lack of functional impairment with preserved left ventricular geometries and systolic function (Fig. 3G, H) .
Klf6 flox/-
;αMHC-Cre mice did not show difference in systolic blood pressure under angiotensin II treatment or pressure-overload compared to Klf6 +/-mice (Supplemental Fig.1I, J) .
These results showed that cardiomyocyte expression of KLF6 is indispensable for cardiac fibrotic progression by angiotensin II, and a possible signaling pathway from cardiomyocytes to cardiac fibroblasts in this process.
Tsp4 is a direct target of KLF6 and has cardioprotective properties
To identify the factor(s) that originate in cardiomyocytes to mediate cardiac fibrosis, genome-wide gene expression profiles for the whole heart between wild-type mice and Klf6 +/-mice under angiotensin II stimulation was done ( Table 1) . Expression levels of candidate factors were screened for genes encoding secreted proteins whose expression levels were significantly changed between the wild-type and knockout mice by RT-PCR analysis. As TSP4 has been reported to prevent excess cardiac fibrosis and dysfunction by pressure overload, 19, 20 we hypothesized that increased Tsp4 expression (3.613 up-fold change) might be involved in attenuated cardiac fibrosis in Klf6 +/-mice under angiotensin II stimulation ( Table 1) . We therefore proceeded to test whether Tsp4 is a target gene of KLF6. Messenger RNA and protein levels of Tsp4 were markedly up-regulated in the heart of both Klf6 +/- (Fig. 4A, C) and Klf6 flox/-;αMHC-Cre mice (Fig.4B ,D) after stimulation. Overexpression of KLF6 in cardiomyocytes showed decreased TSP4 expression levels in cell lysate and also attenuated secretion into medium (Fig.4E) . Immunostaining for TSP4 showed this protein to be localized in the interstitial space of the wild-type heart with angiotensin II stimulation; however increased expression levels in cardiomyocytes were recognized in the
Klf6 flox/-
;αMHC-Cre mice (Supplemental Fig.4 C, D) . Primary cultured cardiomyocytes also expressed TSP4 after angiotensin II treatment (Supplemental Fig. 4E) . At the molecular level, the Tsp4 promoter contains 4 putative KLF-binding motifs (Sp1/Egr-1) at -290 bp from the transcriptional start site (Supplemental Fig. 4A ). Chromatin immunoprecipitation experiments showed direct recruitment of KLF6 to this region under angiotensin II stimulation (Fig. 4F) . Further, reporter analysis of the Tsp4 promoter showed dose-dependent repression by KLF6 overexpression (Fig. 4G) , and mutational analysis of the Tsp4 promoter region revealed this effect was attributed to the Sp1-site most proximal to the transcription start site (Supplemental Fig.4B ). KLF6, therefore, appears to be a negative regulator of Tsp4 transcription.
To clarify the effect of secreted TSP4 from cardiomyocytes on cardiac fibroblasts under angiotensin cardiomyocytes showed higher activation and this effect was also confirmed by co-culture of cardiac fibroblasts with TSP4KO cardiomyocytes (Fig. 5B and Supplemental Fig.4F) . The suppression by TSP4 on cardiac fibroblast activation was thought to be due partly to negative regulation of FAK phosphorylation through the integrin pathway (Fig.5C, D) . KLF6 deletion in the myocardium did not affect apoptosis while proliferation of non-cardiomyoyte cells was reduced. This was thought to be due to reduced cardiac fibroblast activity (Supplemental Fig. 5A-C) .
Taken together, our results showed that KLF6 in cardiomyocytes modulates cardiac fibrosis through negative transcriptional control of TSP4 expression by angiotensin II stimulation.
Discussion
The present study suggests that KLF6 in cardiomyocytes plays a pivotal role in progression of Both whole body and cardiomyocyte-specific deletion of KLF6 resulted in decreased cardiac fibrosis accompanied by preserved cardiac function and increased expression levels of TSP4. Of interest, a phenotype of aggravated fibrosis has been reported in TSP4 knockout mouse heart under pressure-overload. 19, 20 Although their results are based on TAC-treatment and ours are on angiotensin II, cardio-protective effects of TSP4 against cardiac fibrosis are consistent. Several humoral factors such as Tgf1, [21] [22] [23] [24] Fgfs, 25, 26 and gp130/IL6 family factors [27] [28] [29] [30] have been reported to mediate cardiac intracellular regulation. In the present study, we showed that the extracellular matrix protein, TSP4, is centrally involved in intercellular regulation of cardiac fibrosis through the cardiomyocyte to fibroblast, at least through actions of KLF6.
KLF transcription factors are known to be involved in a wide spectrum of cardiac pathologies ranging from heart development 31 to remodeling 32 and in the response to internal and/or external stimuli. 8 Disruption of KLF13 results in perinatal lethal abnormalities of heart development 33 and KLF15 deletion exhibits eccentric cardiac hypertrophy in response to pressure-overload. 34 KLF5 has also been shown to be expressed specifically in the cardiac fibroblast, and to regulate cardiomyocyte hypertrophy through IGF-1 secreted from cardiac fibroblasts. 10 In the present study, we showed that KLF6 in cardiomyocytes regulates cardiomyocyte-specific KLF4 promotes enhanced cardiomyocyte hypertrophy in response to -adrenergic stimulation. 35 These accumulating data indicate the importance of understanding the role of KLFs in a single cell manner to decipher cell-to-cell regulation in cardiac pathologies. Our findings add to our understanding of the collective and cooperative roles that the KLF-related network plays in the cardiac stress response.
TSP4 has been reported to exert a cardioprotective role under pressure-overload, 36, 37 and Tsp4 knockout mice show accelerated cardiac fibrosis under such conditions. 19 Additionally, intracellular TSP4 located in the endoplasmic reticulum (ER) has been reported to alleviate cardiac damage by enhancing adaptation and protection to ER stress, 38 suggesting cell protective effects in both intracellular and extracellular conditions. The role of TSP4 in regulating pathologic remodeling responses in the heart has therefore been the attention of recent interest, and our study identifies a new functional role to this protein. 39 To note, increased expression levels of secreted factors other than Tsp4 (Table 1) were also seen in the heart of KLF6-deleted mice, including periostin which is also known to be a cardioprotective matricellular protein necessary for maintaining fibroblast integrity. 40, 41 As KLF6 is also known as an activator of the TGF signaling pathway, 8 we confirmed modulated TGF secretion and signaling (Supplemental Fig. 6E-G) . KLF6 therefore likely modulates cardiac fibrosis through a multitude of mechanisms and factors with further combinatorial regulation. Intriguingly in liver fibrosis, down-regulation of KLF6 in stellate cells results in activation of fibrogenic genes, and hepatocyte-specific depletion did not alter fibrogenic gene expression or the extent of fibrosis. 42 Accumulating data therefore collectively suggests that KLF6 regulates tissue fibrosis in a context-dependent and cell type-specific manner in each tissue/organ with possible cross-talk regulation which will be addressed in future investigations. 43, 44 In conclusion, we demonstrated that KLF6-mediated signaling from cardiomyocytes to fibroblasts regulated cardiac fibrosis. In this signaling pathway, KLF6 regulated expression levels of the matricellular protein, thrombospondin 4 (TSP4), which further deactivated cardiac fibroblasts. As cardiac fibrosis is a central regulatory process in heart failure as well as in autoimmune disease and malignancies, 1 a better understanding of the underlying mechanisms of the fibrotic process has been anxiously awaited with expectations that this would lead to development of specific therapies for fibrotic organ damage which is presently considered irreversible. KLF6 is likely a pivotal regulator of the fibrotic response, and further investigation of signaling through this molecule in the future will further aid in better understanding not only cardiac fibrosis but also other pathological tissue/organ fibrosis.
by guest on May 22, 2015 . Both mice were subjected to angiotensin II stimulation for 14 days and cardiac fibrosis was analyzed. KLF6 deletion in cardiomyocytes showed significantly less fibrosis than that in the cardiac fibroblast-specific KLF6-deleted mice in response to angiotensin II stimulation. Cardiac fibrosis area was calculated by fibrotic area/ heart area, and then compared to control mice. Scale bar; 1.0 mm. E, F.
KLF6 protein and messenger RNA expression levels were significantly decreased in cardiomyocyte-specific KLF6-deleted mice heart. F. Whole heart messenger RNA was subjected to quantitative PCR. Cardiomyocyte-specific KLF6-deleted mice heart also showed decreased expression levels Chromatin immunoprecipitation was done with KLF6 antibody and refined DNA samples were evaluated by PCR using primer pairs for TSP4 promoter lesion. Input was 5% of the chromatin sample. G. KLF6 expression vector (pCAG-KLF6) and Tsp4 promoter reporter constructs were co-transfected and subjected to evaluation of luciferase reporter activity. Luciferase activity was normalized by protein concentration and relative activities were calculated. Assays were done in triplicate. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01. Accepted Manuscript 
